Soulmaz Fazeli Farsani, PharmD, Msc, PhD

Global Real World Evidence Process/Capability Owner
Boehringer Ingelheim International GmbH
Griesheim, Germany

Disclosure information not submitted.

Presentation(s):

• Risk of acute pancreatitis among new users of empagliflozin compared to sulfonylureas in patients with type 2 diabetes: A Post-Authorization Safety Study

  Saturday, August 26, 2023
  1:15 PM – 1:30 PM ADT